Vericel Corp·4

Feb 13, 4:05 PM ET

MCLAUGHLIN KEVIN F 4

4 · Vericel Corp · Filed Feb 13, 2026

Research Summary

AI-generated summary of this filing

Updated

Vericel (VCEL) Director Kevin McLaughlin Exercises Options, Sells Shares

What Happened

  • Kevin F. McLaughlin, a Vericel (VCEL) director, exercised stock options and sold shares on Feb 11, 2026. He exercised 7,000 options with a $2.63 strike (cost $18,410) and an additional 7,000 shares reported as acquired via conversion at $0.00. He sold 7,000 shares in the open market at $34.66 each, for proceeds of $242,620. The sale was effected under a Rule 10b5-1 trading plan.

Key Details

  • Transaction date: 2026-02-11.
  • Option exercise: 7,000 shares at $2.63 (total cost $18,410) and 7,000 shares reported as acquired at $0.00 (derivative).
  • Sale: 7,000 shares at $34.66 — proceeds $242,620.
  • Footnotes: Sale executed under an automatic Rule 10b5-1 plan adopted March 11, 2024 (F1). The options relate to a 5/3/2017 grant covering 17,500 shares that vested in monthly installments (F2).
  • Shares owned after the transactions: not specified in the Form 4 filing.
  • Filing: Form 4 filed 2026-02-13 for the 2026-02-11 transaction (appears timely).

Context

  • Code meanings: M = option exercise/conversion; S = sale. The exercise and sale occurred the same day, which is commonly seen when insiders exercise options and immediately sell shares (often to cover exercise costs or taxes). Sales under a 10b5-1 plan are pre-arranged trading programs and are typically considered routine. Purchases generally carry more informational weight than routine sales; this filing documents an exercised option followed by an executed sale.

Insider Transaction Report

Form 4
Period: 2026-02-11
Transactions
  • Exercise/Conversion

    Common Stock

    2026-02-11$2.63/sh+7,000$18,41022,100 total
  • Sale

    Common Stock

    [F1]
    2026-02-11$34.66/sh7,000$242,62015,100 total
  • Exercise/Conversion

    Stock Option (Right to Buy)

    [F2]
    2026-02-11+7,0003,500 total
    Exercise: $2.63Exp: 2027-05-03Common Stock (7,000 underlying)
Footnotes (2)
  • [F1]The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024.
  • [F2]These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company.
Signature
/s/ Sean Flynn, as Attorney-in-Fact for Kevin McLaughlin|2026-02-13

Documents

1 file
  • 4
    form4.xmlPrimary

    FORM 4